Syn2bio (WAR:S2B) EBIT: zł Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio EBIT?

Syn2bio WAR:S2B +1.88% 11 EBIT is zł Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Syn2bio's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was zł-28.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Syn2bio's annualized ROC % for the quarter that ended in Sep. 2025 was -145.23%. Syn2bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -900.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Syn2bio  (WAR:S2B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Syn2bio's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-28.933 * ( 1 - 18.34% )/( (13.277 + 19.259)/ 2 )
=-23.6266878/16.268
=-145.23 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20.195 - 0.388 - ( 7.064 - max(0, 0.585 - 7.115+7.064))
=13.277

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26.206 - 8.464 - ( 7.224 - max(0, 8.803 - 7.286+7.224))
=19.259

Note: The Operating Income data used here is one times the annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Syn2bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-28.923/( ( (2.936 + max(-0.505, 0)) + (3.487 + max(-8.641, 0)) )/ 2 )
=-28.923/( ( 2.936 + 3.487 )/ 2 )
=-28.923/3.2115
=-900.61 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.388 + 0 + 0.117)
=-0.505

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -8.8817841970013E-16) - (8.464 + 0 + 0.177)
=-8.641

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Syn2bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=/703.978
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio EBIT Related Terms

Syn2bio EBIT Historical Data

* Premium members only.

The historical data trend for Syn2bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio EBIT Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
EBIT
-13.99 -19.89 -28.92

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
EBIT -13.99 -19.89 -28.92

WAR:S2B vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Syn2bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syn2bio EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syn2bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Syn2bio's EV-to-EBIT falls into.


WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was zł Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of zł Mil mean?
Syn2bio (WAR:S2B) has a EBIT of zł Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Syn2bio.
Is Syn2bio's EBIT too high?
Syn2bio's current EBIT is zł Mil. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's EBIT compare to VRTX and REGN?
Syn2bio's EBIT of zł Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Syn2bio. Syn2bio's current EBIT is zł Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current EBIT of zł Mil. The current EBIT is zł Mil. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current EBIT is zł Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price